More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $239.63 |
|
|||
| Open | $238.12 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $240.79 | ||||
| Day Low | $235.43 | ||||
| P/E | 49.98 | ||||
| EPS | $4.81 | ||||
| Volume | 7,179,747 | ||||
- This pharma giant is positioned for earnings beats as new drug cycle gains pace
- Johnson & Johnson wins FDA approval for TECVAYLI plus DARZALEX FASPRO combo
- Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
- Johnson & Johnson (JNJ) PT Raised to $250 at JPMorgan
- /C O R R E C T I O N -- Johnson & Johnson/
- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Form 4 JOHNSON & JOHNSON For: Feb 27 Filed by: Decker Robert J
- Johnson & Johnson's nipocalimab receives FDA Fast Track designation for lupus
- Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
- Johnson & Johnson (JNJ) PT Raised to $253 at BofA Securities
Entities mentioned with JNJ
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
